ASBMT leadership and past presidents met in late September with industry and BMT thought leaders at the ASBMT Corporate Council meeting. 
Some of the Council’s objectives are to establish meaningful dialogue between industry leaders, healthcare providers and the ASBMT’s leaders. Headed by Armand Keating, MD, the Council aims to share information, advice and assistance to address specific BMT issues.
The Council is about problem solving. Corporate Council members come away from meetings armed with information and council based on the experiences of their peers, who have addressed similar challenges and succeeded. Plus, the open discussion of emerging trends will keep Council members ahead of the curve and able to anticipate future challenges.
This year’s Corporate Council consists of:
Actinium Pharmaceuticals
Amgen, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Chimerix
Gilead Sciences
Incyte
Jazz Pharmaceuticals
Juno Therapeutics
Kite Pharma
Merck & Co., Inc.
Takeda Oncology
OTTR
Pharmacyclics
Sanofi Genzyme
During this year’s meeting discussions focused on the challenges of supportive care after SCT, the role of immune Cell-Based Therapies, Engineered T Cell Therapy, as well as ASBMT’s efforts to improve access and referral for BMT. An overview of health policy issues was also presented by ASBMT Director of Health Policy and Strategic Relations, Stephanie Farnia.
Companies seeking information on the Corporate Council should contact Angie Dahl at AngieDahl@asbmt.org.
Read the entire October 2017 ASBMT eNews here.